December 08, 2020
1 min watch
Save
VIDEO: Romidepsin, brentuximab vedotin shows promise in cutaneous T-cell lymphoma
Romidepsin combined with brentuximab vedotin was well-tolerated in patients requiring systemic therapy for cutaneous T-cell lymphoma, according to phase 1 data presented at ASH Annual Meeting and Exposition.
“What we can learn from it is that it’ll need to be compared to either single agent to see whether it has meaningful improvement or other combinations, but it’s something that can also be explored in non-cutaneous T-cell lymphoma,” Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, told Healio.
Published by:
Sources/Disclosures
Collapse
Source:
Barta SK, et al. Abstract 2970. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Disclosures:
Barta reports consulting for Monsanto; research funding from Seattle Genetics; and receiving honoraria from Acrotech, Atara, Janssen, Pfizer and Seattle Genetics.
Read more about